ArticleJournal of clinical medicine2022
Novel Therapies and Approaches to Inflammatory Bowel Disease (IBD).
Article in Journal of clinical medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Adalimumab Therapy for Crohn's Disease and Axial Spondyloarthritis in Latent Tuberculosis:Sultan Qaboos University medical journal · 2026Pooled it
- ceRNA Network Dynamics in Inflammatory Bowel Disease: The LncRNA-miRNA-mRNA Axis in Intestinal Homeostasis and Inflammation.Cell biochemistry and biophysics · 2026Review
- ST3Gal1 modulates intestinal barrier function and impacts human ulcerative colitis.Molecular medicine reports · 2026Article
- From dysbiosis to precision medicine: targeting the microbial-metabolic axis in IBD management.Frontiers in cellular and infection microbiology · 2026Review
- Crotoxin fromFrontiers in immunology · 2026Article
- Inorganic dietary nanoparticles in intestinal barrier function of inflammatory bowel disease: allies or adversaries?Frontiers in immunology · 2025Review
- SLC6A14 promotes ulcerative colitis progression by facilitating NLRP3 inflammasome-mediated pyroptosis.World journal of gastroenterology · 2024Article
- Modern drug discovery for inflammatory bowel disease: The role of computational methods.World journal of gastroenterology · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Inflammatory bowel diseases (IBDs), divided into two predominant groups, Crohn's disease (CD) and ulcerative colitis (UC), are chronic relapsing inflammatory diseases of the gastrointestinal tract, resulting from an aberrant immune response to microbes in the gut, in genetically susceptible patients [...].
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.